Skip to content

User Acceptability Evaluation of Pseudophakic Patients Previously Implanted With the TECNIS Odyssey IOL

User Acceptability Evaluation of Pseudophakic Patients Previously Implanted With the TECNIS Odyssey IOL

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06005675
Enrollment
44
Registered
2023-08-22
Start date
2023-09-06
Completion date
2024-05-01
Last updated
2025-04-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cataracts

Brief summary

Prospective collection of data from medical records, multicenter, post-market clinical follow-up study.

Interventions

DEVICEIntervention

No study treatments will be administered during this study.

Sponsors

Johnson & Johnson Surgical Vision, Inc.
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

1. Previously bilaterally implanted with TECNIS Odyssey IOL, following cataract extraction; 2. Enrollment at least 21 days after second eye surgery; 3. Clear intraocular media in each eye; 4. Signed informed consent and data protection documentation necessary to comply with applicable privacy laws pertaining to medical treatment in the governing countries; 5. Availability, willingness, ability, and sufficient cognitive awareness to comply with examination procedures; 6. Ability to understand, read, and write in English

Exclusion criteria

1. Concurrent participation in an interventional clinical trial during the time from which the data will be collected; 2. Use of systemic or ocular medication that may affect vision 3. Prior corneal refractive surgery in each eye (i.e., LASIK, PRK, SMILE, RK, CK); NOTE: Limbal relaxing incisions (LRI) are permissible as planned at the time of surgery (intraoperatively) but not postoperatively until after completion of the study visits; 4. Ongoing adverse events that might impact study measurements, as determined by the investigator; 5. Acute or chronic disease or condition, ocular trauma, or surgery that may confound study measurements (e.g., clinically significant macular degeneration, glaucoma, cystoid macular edema, proliferative diabetic retinopathy, keratoconus, etc.); 6. Amblyopia, strabismus, nystagmus in each eye

Design outcomes

Primary

MeasureTime frameDescription
Visual Acuities1-month postoperativeVisual Acuity will be collected via observed case data in units of logMAR.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026